Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency
Recruitment status was: Recruiting
|Psoriasis Vulgaris Vitamin D Deficiency||Dietary Supplement: Vitamin D3 Drug: Placebo|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial|
- Psoriasis Area and Severity Index (PASI Score) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlate with improved clinical outcome (PASI Score) of psoriasis vulgaris.
- Dermatologic Life Qualify Index (DLQI) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlates with better DLQI.
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||February 2012|
|Estimated Primary Completion Date:||February 2012 (Final data collection date for primary outcome measure)|
|Active Comparator: Vitamin D||
Dietary Supplement: Vitamin D3
Vitamin D3, oral supplement, 12 weeks
|Placebo Comparator: Placebo||
Placebo, oral route, 12 weeks
While psoriasis is not a lethal disease, the disease itself can impact patients' quality of life. Nowadays there are several researches on vitamin D functions. Recently review article of vitamin D deficiency by Holick MF., stated that vitamin D can play a role in decreasing the risk of osteoporosis and other chronic diseases such as malignancy, autoimmune disease, infectious disease, cardiovascular disease, and psoriasis. Moreover, vitamin D effects on keratinocyte by decreasing abnormal cell proliferation, differentiation, apoptosis and controlling immunological process via the suppression of T-cell activation, regulation of cytokine secretion patterns, induction of regulatory T-cell, modulation of T-cell proliferation and interference with T-cell apoptosis.
Thus, our objective is to look for other alternative treatment, which may have less side effects and acceptable clinical outcomes.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01339741
|Contact: Chotinij Lertphanichkul, M.D.||662-256-4000 ext email@example.com|
|Contact: Marisa Pongprutthipan, M.D.||662-256-4000 ext firstname.lastname@example.org|
|Chotinij Lertphanichkul, M.D.||Recruiting|
|Patumwan, Bangkok, Thailand, 10330|
|Contact: Chotinij Lertphanichkul, M.D. 662-256-4000 ext 4253 email@example.com|
|Contact: Marisa Pongprutthipan, M.D. 662-256-4000 ext 4253 firstname.lastname@example.org|
|Principal Investigator: Chotinij Lertphanichkul, M.D.|
|Principal Investigator:||Chotinij Lertphanichkul, M.D.||Chulalongkorn University|